|
|
||||||||
Minireview |
1 Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109-0054.
aAddress for correspondence: University Hospital, Room 2G332, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0054.
Abstract
Background: Mass spectrometry (MS) is being introduced into a large number of clinical laboratories. It provides specificity because of its ability to monitor selected mass ions, sensitivity because of the enhanced signal-to-noise ratio, and speed because it can help avoid the need for intensive sample cleanup and long analysis times. However, MS is not without problems related to interference, especially through ion suppression effects. Ion suppression results from the presence of less volatile compounds that can change the efficiency of droplet formation or droplet evaporation, which in turn affects the amount of charged ion in the gas phase that ultimately reaches the detector.
Content: This review discusses materials shown to cause ion suppression, including salts, ion-pairing agents, endogenous compounds, drugs, metabolites, and proteins. Experimental protocols for examining ion suppression, which should include, at a minimum, signal recovery studies using specimen extracts with added analyte, are also discussed, and a more comprehensive approach is presented that uses postcolumn infusion of the analyte to evaluate protracted ionization effects. Finally, this review presents options for minimizing or correcting ion suppression, which include enhanced specimen cleanup, chromatographic changes, reagent modifications, and effective internal standardization.
Summary: Whenever mass spectrometric assays are developed, ion suppression studies should be performed using expected physiologic concentrations of the analyte under investigation.
Mass spectrometry (MS)1 is a powerful qualitative and quantitative analytical technique that has been introduced into many clinical and research laboratories during the last 5 years. The cost of MS analyzers has dropped to a range that is affordable for a majority of laboratories. Compared with a decade ago, instruments are more robust, computer-interfaced, user-friendly, and easier to maintain. There is a greater awareness by manufacturers of the laboratory applications of MS in the clinical laboratory, so that technical support and assay development are high priorities with these companies. In the clinical laboratory, mass spectrometers are used to measure a wide range of clinically relevant analytes. When applied to biological samples, the power of MS lies in its selectivity toward the identification and quantification of compounds. The combination of gas chromatography or HPLC with MS yields a particularly powerful tool. This is especially so for HPLC-MS or HPLC-tandem MS, which is the reason that this combination is being used by many clinical laboratories.
For many years HPLC separations have been monitored through ultraviolet (UV), fluorescence, or electrochemical detection. In reversed-phase HPLC-UV chromatography, more polar compounds are poorly retained on the column and elute at or near the initial void. This is observed as a peak (or peaks) that will interfere with the detection and quantification of the compound of interest. For this reason, sample cleanup is required, and it is the reason that chromatographic runs may be 10 min long. A trade-off often exists, where more extensive sample cleanup may allow shorter chromatographic runs. In contrast, a mass detector can be configured to isolate and quantify specific ions; therefore, sample cleanup and chromatographic separation can theoretically be reduced compared with other, less selective detection modes. Interferences that are apparent with UV detection are not observed with MS when analyte specific masses or product ions are monitored.
Because of the specificity achieved with MS detectors, misconceptions have evolved that (a) chromatographic separation can be minimized or even eliminated, (b) the analytical column is needed only as a mechanism to load sample on the system, (c) specimen cleanup can be minimized or eliminated, and (d) the use of HPLC-MS or HPLC-tandem MS provides absolute accuracy and specificity. However, mass detection is not completely without problems that can compromise or invalidate results.
One important factor that can affect the quantitative performance of a mass detector is ion suppression. Sample matrix, coeluting compounds, and cross-talk can contribute to this effect. Although ion suppression can have potential deleterious effects on both electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI), evidence indicates that the electrospray interface is more likely to be impacted (1). Ionization effects can theoretically occur in either the solution phase or the gas phase. Recent experiments involving ESI of biological extracts have shown that the main cause of ion suppression is a change in the spray droplet solution properties caused by the presence of nonvolatile or less volatile solutes (1). These nonvolatile materials (e.g., salts, ion-pairing agents, endogenous compounds, drugs/metabolites) change the efficiency of droplet formation or droplet evaporation, which in turn affects the amount of charged ion in the gas phase that ultimately reaches the detector. The mass and charge of individual analytes are also factors in making a compound a candidate for ion suppression or in making one compound a source of ion suppression for another. It has been shown that molecules with higher mass will suppress the signal of smaller molecules (2) and that more polar analytes are more susceptible to suppression (3).
The presence of ion suppression or other deleterious effects can be evaluated via several experimental protocols. The first involves comparison of (a) the instrument response for calibrators (including any internal standards) injected directly in mobile phase, (b) the same amount of compound added to preextracted samples, and (c) the same amount of compound added to specimen matrix before extraction (4). The data for the calibrator in mobile phase provide a relative 100% response value. The data for the same amount of compound added to preextracted samples show the effect of sample matrix on MS response (ion suppression), whereas the response data for extracted samples containing the analyte can highlight whether any loss of signal is attributable to the extraction process or ion suppression. It is important to perform the latter two experiments for several specimens to verify that subtle matrix differences do not contribute to a change in MS response. It is also important to evaluate ion suppression that may result from other specimen types (e.g., EDTA or heparin, uremia, lipemia). Fig. 1
shows an actual example of ion suppression attributable to endogenous matrix components. In this experiment, 0.1-mL aliquots of a deidentified donor serum were subjected to three different extraction techniques: solid-phase extraction using a Varian 60-mg Abselut column (water wash, methanol elution), solvent extraction with 0.8 mL of methylene chloride, and protein precipitation with 0.5 mL of acetonitrile. The three dried extracts were reconstituted with 0.5 mL of a caffeine solution (1 mg/L in 100 mL/L methanol plus 10 mL/L formic acid), vortex-mixed, and analyzed by injection (no analytical column) into the mass analyzer. As can be clearly seen in Fig. 1
, all three extracts contained endogenous components that produced ion suppression >90% when compared with a caffeine reference solution of identical concentration.
|
The second protocol, which can be viewed as part of interference checks for an assay, involves injection of drugs or metabolites that may also be present in the specimen. Just because a coeluting drug does not produce similar mass fragments does not mean that this compound is incapable of ion suppression.
The third protocol involves postcolumn continuous infusion of compound into the MS detector (3)(5)(6). The instrumental setup includes a syringe pump connected via a "tee" to the column effluent (Fig. 2
). Because the compound being tested is introduced into the mass detector at a constant rate, a constant ESI response should ideally be observed (Fig. 3A
) if no ionization interferences occur when an extract from a biological specimen, such as serum, is injected into the HPLC portion of the instrument. In actuality it is common to see suppression of the signal at the time point that corresponds to the void volume of the column. The degree of ion suppression and the recovery time to full response can vary from compound to compound (3) and from sample to sample, and can also be dependent on the sample preparation method (Fig. 3, B and C
). Because endogenous compounds from the specimen matrix can continue to elute at any time during the chromatographic run, ion suppression is not limited to the column void. Ion suppression may not be evident during the initial HPLC-MS analysis but may be present during subsequent injections (Fig. 3C
).
|
|
The observed degree of ion suppression can also be dependent on the concentration of the analyte being monitored, which relates to the matrix/analyte ratio. For example, when analyzing clenbuterol in urine, van Hout et al. (7) reported that the percentage of ion suppression for different concentrations of drug using a C18 extraction cartridge ranged from 37% at 93 µg/L to 69% at 45 µg/L. Two important points can be taken from these types of data: (a) they highlight the benefits of decreasing the matrix/analyte ratio through more extensive sample cleanup or through better chromatographic separation; and (b) they show the importance of performing ion suppression validations, such as those outlined in the three protocols above, using concentrations of analyte that reflect those that will be encountered under real conditions.
In addition to the effects of sample matrix components, there are other potential sources of ion suppression to be considered. One is the effect that chromatographic ion-pairing agents may have on signal intensity. For example, trifluoroacetic acid (TFA) has been used in HPLC-UV analyses because it improves peak shape and retention times. Unfortunately, for MS analyses TFA also causes signal suppression and must be dealt with if this acid is used in the mobile phase. Being a component of the mobile phase, this agent will continuously be introduced into the ESI interface, so that signal suppression may be observed throughout the entire chromatographic run.
Fortunately there are several options that can be used to minimize or correct for ion suppression during HPLC-MS analyses. For ion-pairing, other, weaker acids such as acetic, formic, or hexafluorobutyric acid may be successfully substituted for TFA in HPLC-MS analyses. If TFA must be used as an ion-pairing agent to achieve acceptable chromatography and peak shape, it may be possible to decrease the TFA concentration and still obtain adequate separation. The use of surface tension-lowering modifiers in the ESI source has also been reported to be successful when TFA is used as a mobile phase modifier (8). The postcolumn addition of acids and solvent carriers to displace TFA from compounds and aid ionization has also been used successfully. This is a process termed the "TFA Fix" (9). Yamaguchi et al. (10) reported the use of 2-(2-methoxyethoxy)ethanol as a signal enhancer to eliminate the ion-suppressive effects of acetate anions; this agent produced an
100-fold enhancement of the signal for the model drug ibuprofen.
Another way to counter ion suppression is to modify the chromatographic conditions so that the compound(s) of interest elute(s) in a region where ion suppression is not observed. This generally involves increasing the chromatography time, but not always so (11). Because the majority of HPLC assays include an internal standard (stable isotope or structural analog), another approach is to modify the chromatography so that the compound of interest and the internal standard coelute (12). The ion suppression for both compounds should become equal if the peaks chromatographically coincide, thus "correcting" for the degree of suppression. If a stable-isotope internal standard is available, the ion suppression would be identical for the analyte and internal standard. It should be mentioned, however, that the use of an internal standard (even a stable isotope) might not fully solve accuracy or precision problems with the assay if ion suppression exists, as demonstrated in Figs. 1
and 3
. Recall that part of the value of MS lies in the high signal-to-noise ratio achievable with this technique. If ion suppression significantly reduces the signal of the analyte or internal standard, the signal-to-noise may be compromised to a point where accuracy or precision becomes negatively affected. It is for this reason that ion suppression should be evaluated even if an internal standard is included in the assay.
Lastly, because other MS techniques such as Fourier transform (FTMS), matrix-assisted laser desorption/ionization (MALDI), and surface-enhanced laser desorption/ionization (SELDI) are being more widely used, it is worth mentioning that ion suppression is not limited to just HPLC-MS or ESI interfaces, although the discussion in this review has focused on ESI. Arginine-containing peptides have been reported to dominate the peptide pattern for protein digests (13), the extent of which depends on the matrix used. The presence of ionic detergents such as Triton X-100 and Tween 20 has also been shown to cause signal suppression in MALDI experiments, which can be countered by modifications to the matrix (14). Because SELDI also uses the same matrices and ionization process, this technique would be similarly affected.
Footnotes
1 Nonstandard abbreviations: MS, mass spectrometry; UV, ultraviolet; ESI, electrospray ionization; TFA, trifluoroacetic acid; MALDI, matrix-assisted laser desorption/ionization; and SELDI, surface-enhanced laser desorption/ionization. ![]()
References
The following articles in journals at HighWire Press have cited this article:
![]() |
S. Shiraishi, P. W. N. Lee, A. Leung, V. H. H. Goh, R. S. Swerdloff, and C. Wang Simultaneous Measurement of Serum Testosterone and Dihydrotestosterone by Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., November 1, 2008; 54(11): 1855 - 1863. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Marney, T. J. Laha, G. S. Baird, P. M. Rainey, and A. N. Hoofnagle Isopropanol Protein Precipitation for the Analysis of Plasma Free Metanephrines by Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., October 1, 2008; 54(10): 1729 - 1732. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vogeser Instrument-Specific Matrix Effects of Calibration Materials in the LC-MS/MS Analysis of Tacrolimus Clin. Chem., August 1, 2008; 54(8): 1406 - 1408. [Full Text] [PDF] |
||||
![]() |
S. O'Halloran and K. F. Ilett Evaluation of a Deuterium-Labeled Internal Standard for the Measurement of Sirolimus by High-Throughput HPLC Electrospray Ionization Tandem Mass Spectrometry Clin. Chem., August 1, 2008; 54(8): 1386 - 1389. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Nodari, F.-F. Hsu, X. Fu, T. F. Holekamp, L.-F. Kao, J. Turk, and T. E. Holy Sulfated Steroids as Natural Ligands of Mouse Pheromone-Sensing Neurons J. Neurosci., June 18, 2008; 28(25): 6407 - 6418. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kaiser, T. Akerboom, P. Molnar, and H. Reinauer Modified HPLC-Electrospray Ionization/Mass Spectrometry Method for HbA1c Based on IFCC Reference Measurement Procedure Clin. Chem., June 1, 2008; 54(6): 1018 - 1022. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Baerenfaller, J. Grossmann, M. A. Grobei, R. Hull, M. Hirsch-Hoffmann, S. Yalovsky, P. Zimmermann, U. Grossniklaus, W. Gruissem, and S. Baginsky Genome-Scale Proteomics Reveals Arabidopsis thaliana Gene Models and Proteome Dynamics Science, May 16, 2008; 320(5878): 938 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yue, A. L. Rockwood, T. Sandrock, S. L. La'ulu, M. M. Kushnir, and A. W. Meikle Free Thyroid Hormones in Serum by Direct Equilibrium Dialysis and Online Solid-Phase Extraction-Liquid Chromatography/Tandem Mass Spectrometry Clin. Chem., April 1, 2008; 54(4): 642 - 651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. H. Wong, M. J. Sullivan, and G. Cagney Computational methods for the comparative quantification of proteins in label-free LCn-MS experiments Brief Bioinform, March 1, 2008; 9(2): 156 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Annesley Methanol-Associated Matrix Effects in Electrospray Ionization Tandem Mass Spectrometry Clin. Chem., October 1, 2007; 53(10): 1827 - 1834. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Singh and G. Eisenhofer High-Throughput, Automated, and Accurate Biochemical Screening for Pheochromocytoma: Are We There Yet? Clin. Chem., September 1, 2007; 53(9): 1565 - 1567. [Full Text] [PDF] |
||||
![]() |
D. Fliser, J. Novak, V. Thongboonkerd, A. Argiles, V. Jankowski, M. A. Girolami, J. Jankowski, and H. Mischak Advances in Urinary Proteome Analysis and Biomarker Discovery J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1057 - 1071. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sardana, J. Marshall, and E. P. Diamandis Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Culture-Conditioned Medium Clin. Chem., March 1, 2007; 53(3): 429 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Haschke, Y. L. Zhang, C. Kahle, J. Klawitter, M. Korecka, L. M. Shaw, and U. Christians HPLC-Atmospheric Pressure Chemical Ionization MS/MS for Quantification of 15-F2t-Isoprostane in Human Urine and Plasma Clin. Chem., March 1, 2007; 53(3): 489 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Babic, T.S. Larson, S.K. Grebe, S.T. Turner, R. Kumar, and R.J. Singh Application of liquid chromatography-mass spectrometry technology for early detection of microalbuminuria in patients with kidney disease. Clin. Chem., November 1, 2006; 52(11): 2155 - 2157. [Full Text] [PDF] |
||||
![]() |
G. Brandhorst, F. Streit, S. Goetze, M. Oellerich, and V. W. Armstrong Quantification by Liquid Chromatography Tandem Mass Spectrometry of Mycophenolic Acid and Its Phenol and Acyl Glucuronide Metabolites Clin. Chem., October 1, 2006; 52(10): 1962 - 1964. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Hortin The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome Clin. Chem., July 1, 2006; 52(7): 1223 - 1237. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Lensmeyer, D. A. Wiebe, N. Binkley, and M. K. Drezner HPLC Method for 25-Hydroxyvitamin D Measurement: Comparison with Contemporary Assays Clin. Chem., June 1, 2006; 52(6): 1120 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Dervieux, G. Meyer, R. Barham, M. Matsutani, M. Barry, R. Boulieu, B. Neri, and E. Seidman Liquid Chromatography-Tandem Mass Spectrometry Analysis of Erythrocyte Thiopurine Nucleotides and Effect of Thiopurine Methyltransferase Gene Variants on These Metabolites in Patients Receiving Azathioprine/6-Mercaptopurine Therapy Clin. Chem., November 1, 2005; 51(11): 2074 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Cawood, H. P. Field, C. G. Ford, S. Gillingwater, A. Kicman, D. Cowan, and J. H. Barth Testosterone Measurement by Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry: Validation of a Method for Routine Clinical Practice Clin. Chem., August 1, 2005; 51(8): 1472 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schwedhelm, J. Tan-Andresen, R. Maas, U. Riederer, F. Schulze, and R. H. Boger Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of Asymmetric Dimethylarginine in Human Plasma Clin. Chem., July 1, 2005; 51(7): 1268 - 1271. [Full Text] [PDF] |
||||
![]() |
E. Schwedhelm Quantification of ADMA: analytical approaches Vascular Medicine, July 1, 2005; 10(1_suppl): S89 - S95. [Abstract] [PDF] |
||||
![]() |
E. Schwedhelm Quantification of ADMA: analytical approaches Vascular Medicine, May 1, 2005; 10(2_suppl): S89 - S95. [Abstract] [PDF] |
||||
![]() |
T. M. Annesley and L. T. Clayton Quantification of Mycophenolic Acid and Glucuronide Metabolite in Human Serum by HPLC-Tandem Mass Spectrometry Clin. Chem., May 1, 2005; 51(5): 872 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Annesley Application of Commercial Calibrators for the Analysis of Immunosuppressant Drugs in Whole Blood Clin. Chem., February 1, 2005; 51(2): 457 - 460. [Full Text] [PDF] |
||||
![]() |
G. L. Hortin Can Mass Spectrometric Protein Profiling Meet Desired Standards of Clinical Laboratory Practice? Clin. Chem., January 1, 2005; 51(1): 3 - 5. [Full Text] [PDF] |
||||
![]() |
H. Kirchherr and W. N. Kuhn-Velten HPLC-Tandem Mass Spectrometric Method for Rapid Quantification of Dimethylarginines in Human Plasma Clin. Chem., January 1, 2005; 51(1): 249 - 252. [Full Text] [PDF] |
||||
![]() |
R. L. Taylor, S. K. Grebe, and R. J. Singh Quantitative, Highly Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Detection of Synthetic Corticosteroids Clin. Chem., December 1, 2004; 50(12): 2345 - 2352. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Kellogg, J. Behaderovic, O. Bhalala, and N. Rifai Rapid and Simple Tandem Mass Spectrometry Method for Determination of Serum Cotinine Concentration Clin. Chem., November 1, 2004; 50(11): 2157 - 2159. [Full Text] [PDF] |
||||
![]() |
D. Radulovic, S. Jelveh, S. Ryu, T. G. Hamilton, E. Foss, Y. Mao, and A. Emili Informatics Platform for Global Proteomic Profiling and Biomarker Discovery Using Liquid Chromatography-Tandem Mass Spectrometry Mol. Cell. Proteomics, October 1, 2004; 3(10): 984 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Annesley and L. Clayton Simple Extraction Protocol for Analysis of Immunosuppressant Drugs in Whole Blood Clin. Chem., October 1, 2004; 50(10): 1845 - 1848. [Full Text] [PDF] |
||||
![]() |
T. Teerlink, R. Barto, H. J. ten Brink, and C. G. Schalkwijk Measurement of N{epsilon}-(Carboxymethyl)lysine and N{epsilon}-(Carboxyethyl)lysine in Human Plasma Protein by Stable-Isotope-Dilution Tandem Mass Spectrometry Clin. Chem., July 1, 2004; 50(7): 1222 - 1228. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Nelson, S. K. Grebe, D. J. O'Kane, and R. J. Singh Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Measurement of Estradiol and Estrone in Human Plasma Clin. Chem., February 1, 2004; 50(2): 373 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Pfeiffer, Z. Fazili, L. McCoy, M. Zhang, and E. W. Gunter Determination of Folate Vitamers in Human Serum by Stable-Isotope-Dilution Tandem Mass Spectrometry and Comparison with Radioassay and Microbiologic Assay Clin. Chem., February 1, 2004; 50(2): 423 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Lavoie, P. Chessex, T. Rouleau, D. Migneault, and B. Comte Light-Induced Byproducts of Vitamin C in Multivitamin Solutions Clin. Chem., January 1, 2004; 50(1): 135 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Streit, M. Shipkova, V. W. Armstrong, and M. Oellerich Validation of a Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Free and Total Mycophenolic Acid Clin. Chem., January 1, 2004; 50(1): 152 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gervasini, S. Vizcaino, A. G. Herraiz, J. Benitez, and J. A. Carrillo Applicability of an Assay for Routine Monitoring of Highly Variable Concentrations of Olanzapine Based on HPLC with Mass Spectrometric Detection Clin. Chem., December 1, 2003; 49(12): 2088 - 2091. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP |